Chronic Spontaneous Urticaria clinical trials

Explore recruiting chronic spontaneous urticaria clinical trials.

Recruiting chronic spontaneous urticaria studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Spontaneous Urticaria trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.

Hungary, Latvia, Bulgaria, Slovakia, Poland, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

Germany, Denmark, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years.

Poland, Germany, Spain, Netherlands, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients with Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR)

Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)

Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Spontaneous Urticaria trials by city

Chronic Spontaneous Urticaria in Toronto Chronic Spontaneous Urticaria in Vancouver Chronic Spontaneous Urticaria in Montreal Chronic Spontaneous Urticaria in Calgary Chronic Spontaneous Urticaria in Edmonton Chronic Spontaneous Urticaria in Ottawa Chronic Spontaneous Urticaria in Winnipeg Chronic Spontaneous Urticaria in Quebec City Chronic Spontaneous Urticaria in Hamilton Chronic Spontaneous Urticaria in Kitchener Chronic Spontaneous Urticaria in London Chronic Spontaneous Urticaria in Halifax Chronic Spontaneous Urticaria in New York Chronic Spontaneous Urticaria in Los Angeles Chronic Spontaneous Urticaria in Chicago Chronic Spontaneous Urticaria in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease